US5650270A
(en)
|
1982-02-01 |
1997-07-22 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
US5516931A
(en)
|
1982-02-01 |
1996-05-14 |
Northeastern University |
Release tag compounds producing ketone signal groups
|
US4709016A
(en)
|
1982-02-01 |
1987-11-24 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
US4650750A
(en)
|
1982-02-01 |
1987-03-17 |
Giese Roger W |
Method of chemical analysis employing molecular release tag compounds
|
US5360811A
(en)
|
1990-03-13 |
1994-11-01 |
Hoechst-Roussel Pharmaceuticals Incorporated |
1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
|
JP3545461B2
(en)
|
1993-09-10 |
2004-07-21 |
エーザイ株式会社 |
Bicyclic heterocycle-containing sulfonamide derivatives
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
PL218519B1
(en)
|
1999-12-10 |
2014-12-31 |
Pfizer Prod Inc |
PYRROLO[2,3−d]PYRIMIDINE COMPOUNDS
|
DE10002509A1
(en)
|
2000-01-21 |
2001-07-26 |
Gruenenthal Gmbh |
New substituted glutarimide derivatives are IL-12 antagonists, are useful as immunomodulators and for the treatment of angiopathy, hematological or oncological disorders
|
CA2400649A1
(en)
|
2000-02-28 |
2001-09-07 |
Sugen, Inc. |
3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
|
PE20020354A1
(en)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
US7041298B2
(en)
|
2000-09-08 |
2006-05-09 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
EP1389617B1
(en)
|
2001-04-27 |
2007-01-03 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compound and antitumor agent containing the same as active ingredient
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
ES2319894T3
(en)
|
2002-08-14 |
2009-05-14 |
Silence Therapeutics Aktiengesellschaft |
USE OF PROTEIN QUINASA-N-BETA.
|
SG160211A1
(en)
|
2003-04-03 |
2010-04-29 |
Semafore Pharmaceuticals Inc |
Pi-3 kinase inhibitor prodrugs
|
SI1644363T1
(en)
|
2003-05-30 |
2012-07-31 |
Gemin X Pharmaceuticals Canada Inc |
Triheterocyclic compounds, compositions, and methods for treating cancer
|
CA2531069A1
(en)
|
2003-07-03 |
2005-01-27 |
The Trustees Of The University Of Pennsylvania |
Inhibition of syk kinase expression
|
JP4398263B2
(en)
|
2004-01-13 |
2010-01-13 |
富士通株式会社 |
Route design method
|
CN102229609A
(en)
|
2004-05-13 |
2011-11-02 |
艾科斯有限公司 |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
TWI380996B
(en)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
RU2416616C2
(en)
|
2005-01-19 |
2011-04-20 |
Райджел Фармасьютикалз, Инк. |
Prodrugs of 2,4-pyrimidine diamine compounds and use thereof
|
PT2343320T
(en)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anti-gitr antibodies and uses thereof
|
NZ583758A
(en)
|
2005-05-12 |
2011-02-25 |
Abbott Lab |
Apoptosis promoters
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
KR101607288B1
(en)
|
2005-07-01 |
2016-04-05 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
Human monoclonal antibodies to programmed death ligand 1(pd-l1)
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
EA024305B1
(en)
|
2005-10-07 |
2016-09-30 |
Экселиксис, Инк. |
Phosphatidylinositol 3-kinase inhibitors and use thereof
|
RU2597364C2
(en)
|
2005-11-01 |
2016-09-10 |
Таргеджен, Инк. |
Bi-aryl-meta-pyrimidine kinase inhibitors
|
WO2007070514A1
(en)
|
2005-12-13 |
2007-06-21 |
Incyte Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
AU2006332945C1
(en)
|
2005-12-23 |
2013-02-28 |
Wyeth |
Modified lysine-mimetic compounds
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
PI-3 Kinase inhibitors and methods of their use
|
CL2007001165A1
(en)
|
2006-04-26 |
2008-01-25 |
Hoffmann La Roche |
2- (1h-indazol-4-yl) -6- (4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-thieno [3,2-d] pyrimidine; preparation procedure; pharmaceutical composition; process of preparing said composition; pharmaceutical kit; and use to treat diseases such as cancer, immune disorders and cardiovascular diseases.
|
SI2530083T1
(en)
|
2006-09-22 |
2016-09-30 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
US20100279316A1
(en)
|
2007-01-19 |
2010-11-04 |
Leonid Gorelik |
Antibodies to Phosphorylated IRAK4
|
RS54533B1
(en)
|
2007-03-12 |
2016-06-30 |
Ym Biosciences Australia Pty Ltd |
Phenyl amino pyrimidine compounds and uses thereof
|
WO2008118802A1
(en)
|
2007-03-23 |
2008-10-02 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
PE20090717A1
(en)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
|
WO2009009116A2
(en)
|
2007-07-12 |
2009-01-15 |
Tolerx, Inc. |
Combination therapies employing gitr binding molecules
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
CA2960659C
(en)
|
2007-11-09 |
2021-07-13 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
|
CA2707308C
(en)
|
2007-11-30 |
2016-08-02 |
Newlink Genetics Corporation |
Ido inhibitors
|
TWI444382B
(en)
|
2008-03-11 |
2014-07-11 |
Incyte Corp |
Azetidine and cyclobutane derivatives as jak inhibitors
|
JP2011518841A
(en)
|
2008-04-24 |
2011-06-30 |
ニューリンク ジェネティクス, インコーポレイテッド |
IDO inhibitor
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
AR072999A1
(en)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
|
SG196798A1
(en)
|
2008-12-09 |
2014-02-13 |
Genentech Inc |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
US8921037B2
(en)
|
2008-12-16 |
2014-12-30 |
Bo Han |
PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
|
RU2646139C1
(en)
|
2009-09-03 |
2018-03-01 |
Мерк Шарп И Доум Корп. |
Anti-gitr antibodies
|
JP2012254939A
(en)
|
2009-10-07 |
2012-12-27 |
Astellas Pharma Inc |
Oxazole compound
|
ES2601226T3
(en)
|
2009-10-28 |
2017-02-14 |
Newlink Genetics Corporation |
Imidazole derivatives as IDO inhibitors
|
CN102791738B
(en)
|
2009-12-10 |
2015-10-07 |
霍夫曼-拉罗奇有限公司 |
Preferentially in conjunction with the antibody and uses thereof of people CSF1R extracellular domain 4
|
EP4289838A3
(en)
*
|
2010-02-11 |
2024-03-13 |
Celgene Corporation |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
PL2542256T3
(en)
|
2010-03-04 |
2020-01-31 |
Macrogenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
EP2542588A1
(en)
|
2010-03-05 |
2013-01-09 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r and uses thereof
|
EP2542587A1
(en)
|
2010-03-05 |
2013-01-09 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r and uses thereof
|
US8114621B2
(en)
|
2010-03-12 |
2012-02-14 |
Saladax Biomedical Inc. |
Lenalidomide and thalidomide immunoassays
|
EP3943154A1
(en)
|
2010-05-04 |
2022-01-26 |
Five Prime Therapeutics, Inc. |
Antibodies that bind csf1r
|
US9765019B2
(en)
|
2010-06-30 |
2017-09-19 |
Brandeis University |
Small-molecule-targeted protein degradation
|
CN105367577B
(en)
|
2010-07-13 |
2019-04-23 |
弗·哈夫曼-拉罗切有限公司 |
Pyrazolo [1,5A] pyrimidine and thieno [3,2B] pyrimidine derivatives as IRAK4 regulator
|
SG10201506906VA
(en)
|
2010-09-09 |
2015-10-29 |
Pfizer |
4-1bb binding molecules
|
EP2640708A1
(en)
|
2010-11-19 |
2013-09-25 |
Ligand Pharmaceuticals Inc. |
Heterocycle amines and uses thereof
|
EP2649099A4
(en)
|
2010-12-07 |
2016-10-19 |
Univ Yale |
Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
|
NZ612512A
(en)
|
2010-12-09 |
2015-03-27 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
KR101842098B1
(en)
|
2010-12-20 |
2018-03-26 |
메르크 세로노 에스. 에이. |
Indazolyl triazole derivatives as irak inhibitors
|
EP2663312B1
(en)
|
2011-01-10 |
2017-10-11 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
EP2688872A4
(en)
|
2011-03-22 |
2014-08-27 |
Merck Sharp & Dohme |
Amidopyrazole inhibitors of interleukin receptor-associated kinases
|
NO2694640T3
(en)
|
2011-04-15 |
2018-03-17 |
|
|
ES2669310T3
(en)
|
2011-04-20 |
2018-05-24 |
Medimmune, Llc |
Antibodies and other molecules that bind with B7-H1 and PD-1
|
WO2013042137A1
(en)
|
2011-09-19 |
2013-03-28 |
Aurigene Discovery Technologies Limited |
Bicyclic heterocycles as irak4 inhibitors
|
WO2013066729A1
(en)
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
|
PT2785375T
(en)
|
2011-11-28 |
2020-10-29 |
Merck Patent Gmbh |
Anti-pd-l1 antibodies and uses thereof
|
JP6242804B2
(en)
|
2011-12-15 |
2017-12-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Antibody to human CSF-1R and use thereof
|
TW201728592A
(en)
|
2012-01-10 |
2017-08-16 |
林伯士艾瑞斯公司 |
IRAK inhibitors and uses thereof
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
WO2013106643A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
|
WO2013106614A1
(en)
|
2012-01-13 |
2013-07-18 |
Bristol-Myers Squibb Company |
Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
|
JP6109195B2
(en)
|
2012-01-13 |
2017-04-05 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Heterocycle-substituted pyridyl compounds useful as kinase inhibitors
|
WO2013106641A1
(en)
|
2012-01-13 |
2013-07-18 |
Bristol-Myers Squibb Company |
Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
|
MX2014008961A
(en)
|
2012-02-06 |
2014-10-14 |
Genentech Inc |
Compositions and methods for using csf1r inhibitors.
|
AR090263A1
(en)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
|
KR20220162819A
(en)
|
2012-05-11 |
2022-12-08 |
파이브 프라임 테라퓨틱스, 인크. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csfir)
|
AR091649A1
(en)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
|
MX2015000129A
(en)
|
2012-07-10 |
2015-04-14 |
Ares Trading Sa |
Pyrimidine pyrazolyl derivatives.
|
BR112015000561A2
(en)
|
2012-07-11 |
2017-06-27 |
Nimbus Iris Inc |
irak inhibitors and uses thereof
|
WO2014011902A1
(en)
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
US20140018361A1
(en)
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
CN104684582A
(en)
|
2012-08-31 |
2015-06-03 |
戊瑞治疗有限公司 |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
ES2613858T3
(en)
|
2012-09-19 |
2017-05-26 |
F. Hoffmann-La Roche Ag |
2-Oxo-2,3,4,5-tetrahydro-1H-benzo [b] diazepines and their use in the treatment of cancer
|
EP2903613B1
(en)
|
2012-10-08 |
2017-11-22 |
Merck Sharp & Dohme Corp. |
Pyrazole derivatives useful as inhibitors of irak4 activity
|
EP2903617B1
(en)
|
2012-10-08 |
2019-01-30 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
CN104781254B
(en)
|
2012-11-08 |
2016-12-14 |
百时美施贵宝公司 |
Can as kinase modulator through the substituted pyridinyl compounds of heteroaryl
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
CA2900431C
(en)
|
2013-02-07 |
2021-05-04 |
Merck Patent Gmbh |
Pyridazinone-amides derivatives
|
LT2953952T
(en)
|
2013-02-07 |
2017-08-25 |
Merck Patent Gmbh |
Macrocyclic pyridazinone derivatives
|
WO2014143672A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases
|
WO2015048281A1
(en)
|
2013-09-27 |
2015-04-02 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
MY175778A
(en)
|
2013-10-04 |
2020-07-08 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
EA201690952A1
(en)
|
2013-11-08 |
2016-08-31 |
Такеда Фармасьютикал Компани Лимитед |
PYRAZOL FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
|
CN106029650B
(en)
|
2013-11-18 |
2019-10-25 |
豪夫迈·罗氏有限公司 |
Tetrahydro-benzodiazepine * ketone
|
JP6496731B2
(en)
|
2013-11-27 |
2019-04-03 |
シグナルケム・ライフサイエンシーズ・コーポレイションSignalchem Lifesciences Corporation |
Aminopyridine derivatives as TAM family kinase inhibitors
|
TWI667233B
(en)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
Novel indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments
|
AR098991A1
(en)
|
2014-01-03 |
2016-06-22 |
Bristol Myers Squibb Co |
NICOTINAMIDE COMPOUNDS REPLACED WITH HETEROARILE
|
KR20160115933A
(en)
|
2014-01-10 |
2016-10-06 |
오리진 디스커버리 테크놀로지스 리미티드 |
Indazole compounds as irak4 inhibitors
|
CU24389B1
(en)
|
2014-01-13 |
2019-04-04 |
Aurigene Discovery Tech Ltd |
BICYCLIC HETEROCICLYL COMPOUNDS AS IRAK4 INHIBITORS
|
CN106573906A
(en)
|
2014-03-17 |
2017-04-19 |
豪夫迈·罗氏有限公司 |
Piperidine-dione derivatives
|
CN110183440B
(en)
|
2014-03-19 |
2022-04-22 |
勃林格殷格翰国际有限公司 |
Heteroaryl SYK inhibitors
|
HUE044180T2
(en)
|
2014-04-04 |
2019-10-28 |
Pfizer |
Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
|
JP6778114B2
(en)
|
2014-04-14 |
2020-10-28 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
Imid-based proteolysis modulators and related uses
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
BR112016024414A2
(en)
|
2014-04-22 |
2017-08-15 |
Nimbus Iris Inc |
irak inhibitors and uses thereof
|
MX2016017147A
(en)
|
2014-06-20 |
2017-06-07 |
Aurigene Discovery Tech Ltd |
Substituted indazole compounds as irak4 inhibitors.
|
WO2015200795A1
(en)
|
2014-06-27 |
2015-12-30 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
TW201613872A
(en)
|
2014-07-18 |
2016-04-16 |
Biogen Ma Inc |
IRAK4 inhibiting agents
|
US20160022642A1
(en)
|
2014-07-25 |
2016-01-28 |
Yale University |
Compounds Useful for Promoting Protein Degradation and Methods Using Same
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
EP3200790B1
(en)
|
2014-09-30 |
2020-08-26 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
US9969749B2
(en)
|
2014-09-30 |
2018-05-15 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
EP3200788B1
(en)
|
2014-09-30 |
2019-09-18 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
WO2016053772A1
(en)
|
2014-09-30 |
2016-04-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
PT3221306T
(en)
|
2014-11-20 |
2020-02-19 |
Merck Patent Gmbh |
Heteroaryl compounds as irak inhibitors and uses thereof
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
EP3256470B1
(en)
|
2014-12-23 |
2023-07-26 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
MX2017009454A
(en)
|
2015-01-20 |
2017-10-20 |
Arvinas Inc |
Compounds and methods for the targeted degradation of the androgen receptor.
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
EP3267996B1
(en)
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of irak4 activity
|
WO2016144848A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrrolotriazine inhibitors of irak4 activity
|
EP3268367B8
(en)
|
2015-03-12 |
2022-11-16 |
Merck Sharp & Dohme LLC |
Carboxamide inhibitors of irak4 activity
|
WO2016144849A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of irak4 activity
|
WO2016144847A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of irak4 activity
|
WO2016149668A1
(en)
|
2015-03-18 |
2016-09-22 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
GB201504763D0
(en)
|
2015-03-20 |
2015-05-06 |
Mironid Ltd |
Compounds and uses
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
MY189941A
(en)
|
2015-04-22 |
2022-03-22 |
Rigel Pharmaceuticals Inc |
Pyrazole compounds and method for making and using the compounds
|
US20180289685A1
(en)
|
2015-04-30 |
2018-10-11 |
Bayer Pharma Aktiengesellschaft |
Combinations of inhibitors of irak4 with inhibitors of btk
|
BR112017025975B1
(en)
|
2015-06-04 |
2023-12-12 |
Arvinas Operations, Inc |
COMPOUND, COMPOSITION, IN VITRO METHOD FOR INDUCING DEGRADATION OF A TARGET PROTEIN IN A CELL, AND, USE OF A COMPOSITION
|
US20180147202A1
(en)
|
2015-06-05 |
2018-05-31 |
Arvinas, Inc. |
TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
|
US10702527B2
(en)
|
2015-06-12 |
2020-07-07 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
TW201718571A
(en)
|
2015-06-24 |
2017-06-01 |
必治妥美雅史谷比公司 |
Heteroaryl substituted aminopyridine compounds
|
CN105085620B
(en)
|
2015-06-25 |
2018-05-08 |
中山大学附属第一医院 |
A kind of compound for targeting ubiquitination degraded Smad3
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
WO2017004133A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
CA2988430A1
(en)
|
2015-07-10 |
2017-01-19 |
Arvinas, Inc. |
Mdm2-based modulators of proteolysis and associated methods of use
|
BR112017028269A2
(en)
|
2015-07-13 |
2018-09-04 |
Arvinas Inc |
compound, pharmaceutical composition, use of an effective amount of a compound, disease state or condition, and method for identifying a compound.
|
WO2017009650A1
(en)
|
2015-07-14 |
2017-01-19 |
Mission Therapeutics Limited |
Cyanopyrrolidines as dub inhibitors for the treatment of cancer
|
CN108024971A
(en)
|
2015-07-15 |
2018-05-11 |
奥列基因发现技术有限公司 |
Substituted nitric heterocyclic compound as IRAK-4 inhibitor
|
AU2016293441A1
(en)
|
2015-07-15 |
2018-02-01 |
Aurigene Discovery Technologies Limited |
Indazole and azaindazole compounds as IRAK-4 inhibitors
|
WO2017030814A1
(en)
|
2015-08-19 |
2017-02-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
CN107949559B
(en)
|
2015-08-27 |
2020-12-11 |
辉瑞公司 |
Bicyclic fused heteroaryl or aryl compounds as IRAK4 modulators
|
KR20180064382A
(en)
|
2015-09-18 |
2018-06-14 |
메르크 파텐트 게엠베하 |
Heteroaryl compounds as IRAK inhibitors and uses thereof
|
MX2018002986A
(en)
|
2015-09-18 |
2018-05-02 |
Merck Patent Gmbh |
Heteroaryl compounds as irak inhibitors and uses thereof.
|
US10526309B2
(en)
|
2015-10-02 |
2020-01-07 |
The University Of North Carolina At Chapel Hill |
Pan-TAM inhibitors and Mer/Axl dual inhibitors
|
US20190192532A1
(en)
|
2015-10-02 |
2019-06-27 |
Dana-Farber Cancer Institute |
Combination therapy of bromodomain inhibitors and checkpoint blockade
|
EP3370715A4
(en)
|
2015-11-02 |
2019-05-15 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
JP6895439B2
(en)
|
2015-12-22 |
2021-06-30 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Pyrazolo [1,5a] pyrimidine derivative as an IRAK4 regulator
|
WO2017117473A1
(en)
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molescules for her3 degradation and methods of use
|
WO2017117474A1
(en)
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional compounds for her3 degradation and methods of use
|
ES2904557T3
(en)
|
2016-01-20 |
2022-04-05 |
Biogen Ma Inc |
Iraq4 inhibitory agents
|
CA3017740A1
(en)
|
2016-03-16 |
2017-09-21 |
Pearlie BURNETTE |
Small molecules against cereblon to enhance effector t cell function
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
RU2021102253A
(en)
|
2016-04-06 |
2021-03-03 |
Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган |
DESTRUCTORS OF MDM2 PROTEIN
|
EP3440082A1
(en)
|
2016-04-06 |
2019-02-13 |
The Regents of The University of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
CN109562113A
(en)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
Loop coil degron body for target protein degradation
|
CN109562107A
(en)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
Heterocycle degron body for target protein degradation
|
WO2017197051A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Amine-linked c3-glutarimide degronimers for target protein degradation
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
PL3458101T3
(en)
|
2016-05-20 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Protac antibody conjugates and methods of use
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017207385A1
(en)
|
2016-05-31 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Substituted 3-methylindazoles, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
|
GB201610147D0
(en)
|
2016-06-10 |
2016-07-27 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
US10710983B2
(en)
|
2016-06-27 |
2020-07-14 |
Rigel Pharmaceuticals, Inc. |
2,4-diamino-pyrimidine compounds and method for making and using the compounds
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
JP2019196309A
(en)
|
2016-09-15 |
2019-11-14 |
武田薬品工業株式会社 |
Heterocyclic compound
|
US10925868B2
(en)
|
2016-11-10 |
2021-02-23 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
|
EP3544970B1
(en)
|
2016-11-22 |
2021-11-17 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
|
WO2018119441A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas, Inc. |
Egfr proteolysis targeting chimeric molecules and associated methods of use
|
KR20190116315A
(en)
|
2017-01-31 |
2019-10-14 |
아비나스 오퍼레이션스, 인코포레이티드 |
Cereblon Ligand and Bifunctional Compounds Comprising the Same
|
JOP20180011A1
(en)
|
2017-02-16 |
2019-01-30 |
Gilead Sciences Inc |
PYRROLO[1,2-b] PYRIDAZINE DERIVATIVES
|
HUE056493T2
(en)
|
2017-05-11 |
2022-02-28 |
Bristol Myers Squibb Co |
Thienopyridines and benzothiophenes useful as irak4 inhibitors
|
EP3641762A4
(en)
|
2017-06-20 |
2021-03-10 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
WO2019043214A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
Glutarimide
|
JP7366031B2
(en)
|
2017-09-22 |
2023-10-20 |
カイメラ セラピューティクス, インコーポレイテッド |
Proteolytic agents and their use
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-hydroxypyrrolidin-2-yl)-hydroxamate compounds and methods of use thereof
|
EP3700901A1
(en)
|
2017-10-24 |
2020-09-02 |
Genentech, Inc. |
(4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
Degraders and degrons for targeted protein degradation
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
BR112020012997A2
(en)
|
2017-12-26 |
2020-12-01 |
Kymera Therapeutics, Inc. |
irak degraders and uses thereof
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
AU2019220632B2
(en)
|
2018-02-14 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
IRAK degraders and uses thereof
|
WO2019165229A1
(en)
|
2018-02-23 |
2019-08-29 |
Dana-Farber Cancer Institute, Inc. |
Small molecules for inducing selective protein degradation and uses thereof
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
WO2020010210A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
US20220348556A1
(en)
|
2018-07-06 |
2022-11-03 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
WO2020018788A1
(en)
|
2018-07-20 |
2020-01-23 |
Dana-Farber Cancer Institute, Inc. |
Degraders that target proteins via keap1
|
WO2020113233A1
(en)
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
WO2020251974A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
WO2020251971A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
US20230087825A1
(en)
|
2019-06-10 |
2023-03-23 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
KR20220032063A
(en)
*
|
2019-06-28 |
2022-03-15 |
카이메라 쎄라퓨틱스 인코포레이티드 |
IRAK disintegrants and uses thereof
|
WO2020264490A1
(en)
|
2019-06-28 |
2020-12-30 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
WO2021011634A1
(en)
|
2019-07-15 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2021011631A1
(en)
|
2019-07-15 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Fused-glutarimide crbn ligands and uses thereof
|
WO2021011871A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
JP2022548095A
(en)
|
2019-09-16 |
2022-11-16 |
ノバルティス アーゲー |
Adhesive decomposer and its usage
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
JP2023509366A
(en)
|
2019-12-17 |
2023-03-08 |
カイメラ セラピューティクス, インコーポレイテッド |
IRAK dissolving agents and their uses
|
WO2021127278A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|